Theralase Technologies (CVE:TLT) Shares Up 3.5% - What's Next?

Theralase Technologies Inc. (CVE:TLT - Get Free Report)'s stock price shot up 3.5% during trading on Tuesday . The stock traded as high as C$0.30 and last traded at C$0.30. 81,515 shares were traded during mid-day trading, a decline of 23% from the average session volume of 105,486 shares. The stock had previously closed at C$0.29.

Theralase Technologies Stock Performance

The company has a market capitalization of C$68.18 million, a P/E ratio of -14.91 and a beta of 1.36. The company has a debt-to-equity ratio of 14.85, a quick ratio of 3.40 and a current ratio of 1.91. The stock has a fifty day moving average of C$0.27 and a 200 day moving average of C$0.24.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.